Drugs / SyB L-1101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01700335 | Jun 2012 → Feb 2015 | myelodysplastic syndrome | SymBio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SyB L-1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01700335 ↗ |
| Known as | rigosertib sodium | “SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.” NCT01700335 ↗ |
| Route | Intravenous | “The dose will be administered intravenously for 72 continuous hours (3 days)” NCT01700335 ↗ |